Table 4. SIRs and 95% CIs for development of lymphoma subtypes in subgroups of solid organ transplant recipients by time since transplant, United States, 1987–2008.
|
Time since transplant |
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| |
1–360 days |
361–1800 days |
1801+ days |
Poisson |
||||||
| Subtype | n | SIR | 95% CI | n | SIR | 95% CI | n | SIR | 95% CI | P-value* |
|
B-cell lymphoma subtype | ||||||||||
| Burkitt's lymphoma/leukaemia | <3 | 3.3 | 0.4–11.8 | 54 | 31.7 | 23.8–41.3 | 32 | 25.0 | 17.1–35.3 | <0.0001 |
| Chronic lymphocytic lymphoma/small lymphocytic lymphoma | 11 | 1.4 | 0.7–2.4 | 12 | 0.5 | 0.3–0.9 | 13 | 0.6 | 0.3–1.0 | 0.05 |
| Diffuse large B-cell lymphoma | 335 | 30.1 | 26.9–33.5 | 305 | 9.4 | 8.4–10.5 | 308 | 11.6 | 10.4–13.0 | <0.0001 |
| Follicular lymphoma | 13 | 2.1 | 1.1–3.5 | 8 | 0.4 | 0.2–0.9 | 17 | 1.1 | 0.6–1.8 | 0.0014 |
| Lymphoplasmacytic lymphoma | 3 | 3.5 | 0.7–10.4 | 6 | 2.3 | 0.9–5.1 | 7 | 3.0 | 1.2–6.2 | 0.81 |
| Mantle cell | <3 | 0.8 | 0.0–4.7 | <3 | 0.3 | 0.0–1.5 | <3 | 0.3 | 0.0–1.6 | 0.71 |
| Marginal zone |
6 |
2.7 |
1.0–5.9 |
13 |
1.9 |
1.0–3.2 |
16 |
2.4 |
1.4–3.9 |
0.69 |
| Splenic/nodal marginal zone |
<3 |
1.3 |
0.0–7.5 |
<3 |
0.4 |
0.0–2.4 |
4 |
1.7 |
0.5–4.4 |
0.38 |
| MALT type |
5 |
3.4 |
1.1–7.9 |
12 |
2.6 |
1.4–4.6 |
12 |
2.8 |
1.5–4.9 |
0.89 |
|
T-cell lymphoma subtype | ||||||||||
| Peripheral T-cell lymphoma | <3 | 1.7 | 0.2–6.2 | 11 | 3.2 | 1.6–5.7 | 17 | 5.7 | 3.3–9.1 | 0.11 |
| ALCL | 15 | 32.8 | 18.4–54.1 | 5 | 3.7 | 1.2–8.7 | 16 | 15.6 | 8.9–25.4 | <0.0001 |
| Primary cutaneous ALCL | 3 | 32.4 | 6.7–94.7 | <3 | 3.5 | 0.1–19.6 | 5 | 17.1 | 5.6–40.0 | 0.08 |
| Mycosis fungoides/Sézary's syndrome | <3 | 2.4 | 0.3–8.7 | <3 | 0.8 | 0.1–3.1 | 4 | 2.3 | 0.6–5.8 | 0.42 |
| Hepatosplenic T-cell lymphoma | 0 | 0.0 | 0.0–451.4 | <3 | 42.7 | 1.1–238.0 | 4 | 219 | 60–560 | 0.10 |
| NK/TCL, nasal type |
<3 |
11.9 |
0.3–66.33 |
3 |
12.3 |
2.6–36.1 |
4 |
19.4 |
5.3–48.6 |
0.81 |
| All T-cell lymphoma |
20 |
11.5 |
7.0–17.8 |
18 |
3.5 |
2.1–5.5 |
42 |
9.7 |
7.0–13.1 |
<0.0001 |
| Precursor B- or T-cell lymphoblastic leukaemia/lymphoma |
<3 |
1.2 |
0.1–4.2 |
11 |
2.4 |
1.2–4.3 |
6 |
2.0 |
0.7–4.3 |
0.59 |
| NHL, other |
0 |
0.0 |
0.0–4.3 |
5 |
2.0 |
0.7–4.7 |
4 |
2.1 |
0.6–5.4 |
0.20 |
| NHL, not otherwise specified |
115 |
20.2 |
16.7–24.3 |
124 |
7.8 |
6.5–9.3 |
93 |
8.4 |
6.8–10.3 |
<0.0001 |
| All NHL |
511 |
12.4 |
11.3–13.5 |
561 |
4.6 |
4.3–5.0 |
545 |
5.5 |
5.0–6.0 |
<0.0001 |
| Hodgkin's lymphoma | 6 | 1.4 | 0.5–3.1 | 36 | 3.2 | 2.2–4.4 | 41 | 5.4 | 3.9–7.3 | 0.001 |
Abbreviations: ALCL=anaplastic large-cell lymphoma; CI=confidence interval; MALT=mucosa-associated lymphoid tissue; NHL=non-Hodgkin's lymphoma; NK=natural killer; SIR=standardised incidence ratio; TCL=T-cell lymphoma.
*P-value from univariate Poisson regression testing for heterogeneity across categories.
Bold indicates SIRs significantly different from 1 at P<0.05.